Drug Profile


Alternative Names: Marizev; MK-3102

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Merck & Co
  • Class 2 ring heterocyclic compounds; Antihyperglycaemics; Fluorobenzenes; Pyrazoles; Pyrrolidines; Small molecules; Sulfonamides
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 31 May 2016 Merck terminates a phase III trial for Type-2 diabetes mellitus in USA, Austria, Belgium, Croatia, Czech Republic, Denmark, Finland, France, Germany, Hungary, Italy, Lithuania, the Netherlands, Poland, Spain and Sweden due to business reasons (NCT01703208)
  • 07 Apr 2016 Gifu University Graduate School of Medicine and Yamada hospital plan a clinical trial for Type-2 diabetes mellitus (In the elderly) in Japan (unspecified) (UMIN000021815)
  • 01 Mar 2016 Merck completes a phase III trial in Type-2 diabetes mellitus in USA, Hungary, Slovakia, Spain, Bulgaria, Poland and Romania (NCT01755156; EudraCT2012-003670-11 )
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top